Evaluation of PPAR-α Agonist effect on Kidney Performance Through Increment of Nitric Oxide During Hyperglycemia-Induced Nephropathy in Rat

Authors

Department of Physiology and Biophysics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Background: Chronic uncontrolled hyperglycemia is the common reason of renal failure.
 

Objectives: We aimed to assess the possible protective effects of PPAR-α agonist (fenofibrate) on kidney performance and nitric oxide (NO) level of kidney in experimental model of diabetic nephropathy (DN).
 

Methods: Male Wistar rats were randomly divided into four groups (n = 6); Normal, Normal treatment, Diabetic and Diabetic treatment. Rats were made diabetic by an intravenous injection of streptozotocin (40 mg/kg). After 72 hours, blood samples were collected for approving diabetes and the rats with blood glucose above 400 mg/dL were considered as diabetic animals. Treated groups received orally fenofibrate for 8 weeks (80 mg/kg/day). At the end, blood samples were collected for measuring blood glucose and creatinine. Finally, NO content and histopathological assessments of kidney were assessed at termination of experiment.
 

Results: Fenofibrate did not change the blood glucose of normal or diabetic rats. Diabetes increased the proteinuria (82%) and blood creatinine of diabetic rats (4.51 ± 0.45 mg/dL) compared to normal rats (0.66 ± 0.14 mg/dL). Chronic hyperglycemia also decreased the content of renal NO (37%) compared with normal rats in accompany with histopathological damages. Fenofibrate significantly decreased the proteinuria (80%) and blood creatinine of diabetic rats (1.66±0.23 mg/dL). The content of NO increased in the kidney of both treated rats (31%). Fenofibrate also improved the histopathological changes of diabetic kidney.
 

Conclusions: Our findings indicate that fenofibrate (PPAR-αagonist) is able to prevent DN progression and improve kidney performance during chronic uncontrolled hyperglycemia possibly through increase in NO bioavailability of kidney.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1.Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, GarciaPerez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327-40. [PubMed: 21537349].
https://doi.org/10.1038/nrneph.2011.51
PMid:21537349
 
2. Fraser DJ, Phillips AO. Diabetic nephropathy. Medicine.2007;35(9):503-6.
https://doi.org/10.1016/j.mpmed.2007.06.007
 
3. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropathol. 2013;2(1):20-7. doi: 10.5812/nephropathol.9093. [PubMed: 24475422].
https://doi.org/10.5812/nephropathol.9093
PMid:24475422 PMCid:PMC3886179
 
4. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabeticnephropathy. Diabetes Res Clin Pract. 2008;82 Suppl 1:S30-7 [PubMed: 18937992].
https://doi.org/10.1016/j.diabres.2008.09.032
PMid:18937992
 
5. Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58(4):259-71. [PubMed: 23313806].
https://doi.org/10.1016/j.vph.2013.01.001
PMid:23313806
 
6. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol. 2000;11(1):71-9. [PubMed:10616842].
https://doi.org/10.1681/ASN.V11171
PMid:10616842
 
7. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, CampbellThompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18(2):539-50. [PubMed:17202420].
https://doi.org/10.1681/ASN.2006050459
PMid:17202420
 
8. Brodsky SV, Gao S, Li H, Goligorsky MS. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol. 2002;283(5):H2130-9. [PubMed: 12384491].
https://doi.org/10.1152/ajpheart.00196.2002
PMid:12384491
 
9. Da Silva-Azevedo L, Baum O, Zakrzewicz A, Pries AR. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem Biophys Res Commun. 2002;297(5):1270-6. [PubMed: 12372425].
https://doi.org/10.1016/S0006-291X(02)02370-7
PMid:12372425
 
10. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol.2002;161(1):239-48.. [PubMed:12107108].
https://doi.org/10.1016/S0002-9440(10)64175-2
PMid:12107108
 
11. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation.2002;105(9):1110-5. [PubMed: 11877364].
https://doi.org/10.1161/hc0902.104718
PMid:11877364
 
12. Cheng H, Wang H, Fan X, Paueksakon P, Harris RC. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int. 2012;82(11):1176-83. [PubMed: 22785174].
https://doi.org/10.1038/ki.2012.248
PMid:22785174 PMCid:PMC3473143
 
13. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43(5):522-31.[PubMed: 23480615].
https://doi.org/10.1111/eci.12068
PMid:23480615
 
14. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, et al. Accelerated diabetic nephropathy in mice lacking the peroxisomeproliferator-activated receptor alpha. Diabetes. 2006;55(4):885-93. [PubMed: 16567507].
https://doi.org/10.2337/diabetes.55.04.06.db05-1329
PMid:16567507
 
15. Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood). 2010;235(3):383-91. [PubMed: 20404057].
https://doi.org/10.1258/ebm.2009.009218
PMid:20404057 PMCid:PMC3057137
 
16. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212(2):167-78. [PubMed:16490224].
https://doi.org/10.1016/j.taap.2006.01.003
PMid:16490224
 
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem. 1976;72:248-54. [PubMed: 942051].
https://doi.org/10.1006/abio.1976.9999
PMid:942051
 
18. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol. 2008;294(1):F1-9. [PubMed: 17928410].
https://doi.org/10.1152/ajprenal.00424.2007
PMid:17928410
 
19. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933-53. [PubMed: 1394976].
https://doi.org/10.1093/clinchem/38.10.1933
PMid:1394976
 
20. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316(7130):504-9. [PubMed: 9501711].
https://doi.org/10.1136/bmj.316.7130.504
PMid:9501711 PMCid:PMC2665663
 
21. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7(6):930-7. [PubMed: 8793803].
https://doi.org/10.1681/ASN.V76930
PMid:8793803
 
22. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care. 1999;22(8):1245-51. [PubMed: 10480765].
https://doi.org/10.2337/diacare.22.8.1245
PMid:10480765
 
23. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem. 2009;320(1-2):149-62. [PubMed: 18830571].
https://doi.org/10.1007/s11010-008-9917-z
PMid:18830571
 
24. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res. 2008;57(5):199-204. [PubMed: 18465086].
https://doi.org/10.1007/s00011-006-6190-z
PMid:18465086
 
25. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30(8):1945-51. [PubMed: 17483155].
https://doi.org/10.2337/dc07-0015
PMid:17483155
 
26. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem. 2001;276(32):30392-8. [PubMed: 11402048].
https://doi.org/10.1074/jbc.M103702200
PMid:11402048
 
27. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, et al. Peroxisome proliferator-activated receptor alpha agonists 6 Razavi Int J Med. 2016
 
4(2):e37670. Yaribeygi H and Mohammadi MT increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24(4):658-63. [PubMed: 14751809].
https://doi.org/10.1161/01.ATV.0000118682.58708.78
PMid:14751809
Razavi International Journal of Medicine
Volume 4, Issue 2
April 2016
Pages 35-41

Files

Share

How to cite

Statistics